



Benchmark®

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in doubt as to what action you should take, you are recommended to seek your own financial advice immediately from your stockbroker, bank manager, solicitor, accountant or other professional adviser authorised under the Financial Services and Markets Act 2000 if you are in the United Kingdom, or if you are outside the United Kingdom, from another appropriately authorised independent adviser.

If you have sold or transferred all of your registered holding of ordinary shares in the Company please forward this document, together with the accompanying Form of Proxy, as soon as possible to the purchaser or transferee or to the stockbroker, bank manager or other agent through whom the sale or transfer was effected for delivery to the purchaser or transferee.

Notice of Annual General Meeting

Benchmark Holdings plc

(Registered in England and Wales with no. 04115910)

Notice of the Annual General Meeting (the “**AGM**”) of Benchmark Holdings plc (the “**Company**”) to be held at DLA Piper UK LLP, 160 Aldersgate Street, London EC1A 4HT at 11.00 a.m. (UK time) on 11 March 2025 is set out at the end of this document and the recommendation of the Directors is set out on page 5.

Unless otherwise stated, all references to times in this document are to London time.

BENCHMARK HOLDINGS PLC

(Registered in England and Wales with no. 04115910)
Registered Office
Highdown House
Yeoman Way
Worthing
West Sussex
BN99 3HH

**Benchmark**[®]

11 February 2025

Directors

Trond Williksen
Septima Maguire
Nathan "Tripp" Lane*
Kristian Eikre*
Yngve Myhre*
Torgeir Svae*
Marie Danielsson*
Jonathan Esfandi*

*Non-executive Directors

To holders of Ordinary Shares of £0.001 each in the Company

Dear Shareholder

This letter accompanies the 2024 Annual Report and gives details of the business to be transacted at the 2025 AGM of the Company.

Annual General Meeting

Notice of the Annual General Meeting is given on page 6.

Resolutions 1 to 13 will be proposed as ordinary resolutions and resolutions 14 to 16 will be proposed as special resolutions.

Resolution 1 — Company's Annual Report and Accounts 2024 (ordinary resolution)

Company law requires the Directors to present to the Annual General Meeting the Annual Accounts, the Directors' Report and the Auditors' Report on these accounts.

Resolution 2 — Directors' Remuneration Report (ordinary resolution)

Whilst AIM traded companies are not required by company law to present a Directors' Remuneration Report to their shareholders for a vote, your Board has decided that the Directors' Remuneration Report for the year ended 30 September 2024 should be subject to a shareholder vote. The Directors' Remuneration Report appears on pages 84 to 92 of the 2024 Annual Report, which is also available on the Company's website at www.benchmarkplc.com. This shareholder vote is advisory only and therefore does not directly affect the remuneration paid to any Director.

Resolutions 3 and 4 — Reappointment of Auditors and determination of their remuneration (ordinary resolutions)

Company law requires the Company to appoint auditors at each Annual General Meeting at which accounts are presented, to hold office until the conclusion of the next such meeting. The Board proposes the reappointment of KPMG LLP as auditors of the Company for the year ended 30 September 2025 (Resolution 3). Resolution 4 authorises the Directors, in accordance with standard practice, to negotiate and agree the remuneration of the auditors. In practice, the Audit Committee will consider the audit fees for recommendation to the Board.

Resolutions 5 to 12 (inclusive) — Election and Re-election of Directors (ordinary resolutions)

The articles of association of the Company (the "**Articles**") require that each Director shall be subject to annual re-election in accordance with the 2018 UK Corporate Governance Code. The Articles also provide that the Board has the power to appoint any person to be a Director, and that any Director appointed by the Board shall only hold office until the next following AGM.

The Board supports the election of Nathan "Tripp" Lane who was appointed as a Director by the Board on 17 December 2024, and so has not been subject to a vote by shareholders.

Mr Lane is a founding partner of Delancey Cove LLC, an advisory firm focused on transitional governance and management of both private and public companies across all stages of their cycle.

All Directors standing for re-election were all last elected at the AGM of the Company held in 2024. Accordingly, all such Directors are required under the Articles to stand for re-election at the 2025 AGM. Resolutions 5 to 12 inclusive therefore propose the election of Nathan "Tripp" Lane and the re-election of all the other Directors.

The Directors believe that the Board offers an appropriate balance of knowledge and skills and that all the non-executive Directors (with the exception of Torgeir Svae, Jonathan Esfandi and Kristian Eikre) are independent in character and judgement. Kristian Eikre is not deemed to be independent due to his relationship with FERD AS (the Company's largest shareholder as at the date of this document). Torgeir Svae acts as shareholder representative of Kverva AS, a significant shareholder in the Company, and Jonathan Esfandi acts as shareholder representative of JNE, a significant shareholder of the Company, and therefore the Board has concluded that they are not independent directors of the Company. The Board has considered and recommends the appointment of all of the Directors of the Company standing for election and re-election.

Brief biographies of the Directors outlining their skills, contribution and experience are available on the Company's website at: www.benchmarkplc.com/investors/the-board.

Resolution 13 — Authority to allot shares or grant subscription or conversion rights (ordinary resolution)

This resolution asks shareholders to grant the Directors authority under section 551 of the Companies Act 2006 (the “Act”) to allot shares or grant such subscription or conversion rights as are contemplated by sections 551(1)(a) and (b) respectively of the Act up to a maximum aggregate nominal value of £494,272, being approximately two thirds of the nominal value of the issued share capital of the Company as at 7 February 2025 (being the latest practicable date prior to the publication of this document). £247,136 of this authority, being approximately one third of the nominal value of the used share capital of the Company is reserved only for a fully pre-emptive offer.

This is the maximum permitted amount under best practice corporate governance guidelines and in line with The Investment Association's Share Capital Management Guidelines. The authority will expire at the next Annual General Meeting, or if earlier, the date falling 15 months after passing of the resolution. The Directors consider it important to have the maximum ability and flexibility commensurate with good corporate governance guidelines to raise finance to enable the Company to respond to market development and conditions.

Resolutions 14 and 15 — Disapplication of pre-emption rights (special resolutions)

If the Directors wish to allot new shares or other equity securities for cash, the Act requires that such shares or other equity securities are offered first to existing shareholders in proportion to their existing holding. The allotment of equity securities as referred to in Resolutions 14 and 15 includes the sale of any shares which the Company holds in treasury following a purchase of its own shares.

Although the Pre-Emption Group's Statement of Principles on Disapplying Pre-Emption Rights published in November 2022 (the “Statement of Principles”) allows the Company to disapply higher percentages, in light of feedback received by the Directors following consultation with major shareholders, the Company is proposing to disapply pre-emption rights up to 5 per cent. of the Company's relevant issued ordinary share capital and to disapply pre-emption rights up to an additional 5 per cent. of the Company's relevant issued ordinary share capital for acquisitions or other capital investments as defined by the Statement of Principles. These percentages are in line with what has been approved by shareholders in the years prior to the 2024 annual general meeting of the Company. The Company is not seeking any authority for follow-on offers.

Resolution 14 asks shareholders to grant the Directors authority to allot equity securities for cash up to an aggregate nominal value of £37,070, being approximately 5 per cent. of the nominal value of the issued share capital of the Company as at 7 February 2025 (being the latest practicable date prior to the publication of this document), without first offering the securities to existing shareholders. Resolution 14 also disapplies the statutory pre-emption provisions in connection with a fully pre-emptive offer only in relation to the amount permitted under Resolution 13.2 allowing the Directors to make appropriate arrangements in relation to fractional entitlements or other legal or practical problems which might arise.

Resolution 15 asks shareholders to grant the Directors an additional authority to allot equity securities for cash up to an aggregate nominal value of £37,070, being approximately 5 per cent. of the nominal value of the issued share capital of the Company as at 7 February 2025 (being the latest practicable date prior to the publication of this document), for the purposes of financing or refinancing an acquisition or other capital investment of a kind contemplated by the Statement of Principles.

The Directors confirm that, in considering the exercise of the authority under Resolutions 14 and 15, they intend to follow the shareholder protections set out in Part 2B of the Pre-emption Group's Statement of Principles to the extent reasonably practicable and relevant (as the Company is not seeking authority for follow-on offers).

The authorities in Resolutions 14 and 15 will expire at the next Annual General Meeting, or if earlier, the date falling 15 months after passing of the resolutions.

Resolution 16 — Purchases of own shares by the Company (special resolution)

Resolution 16 seeks authority from shareholders for the Company to make market purchases of its own ordinary shares, such authority being limited to the purchase of up to 74,141,019 ordinary shares (being approximately 10 per cent. of the Company's issued ordinary share capital as at 7 February 2025 (being the latest practicable date prior to the publication of this document)). The maximum and minimum prices payable are also limited in the resolution.

The authority will only be exercised if the Directors consider that there is likely to be a beneficial impact on earnings per ordinary share and that it is in the best interests of the Company, and its shareholders generally, at the time. The Company will be able to hold the ordinary shares which have been repurchased as treasury shares and re-sell them for cash, cancel them or use them for the purposes of its employee share schemes.

Options and warrants to subscribe for up to 32,817,776 ordinary shares have been granted and are outstanding as at 7 February 2025 (being the latest practicable date prior to publication of this document) representing 4.43 per cent. of the issued ordinary share capital at that date. If the Directors were to exercise in full the power for which they are seeking authority under Resolution 16, the options outstanding as at 7 February 2025 (being the latest practicable date prior to the publication of this document) would represent 4.92 per cent. of the ordinary share capital (excluding any shares held in treasury) in issue following such exercise.

Action to be taken

If you are a registered shareholder, you are asked to:

1. complete the enclosed Form of Proxy and return it, together with any power of attorney or other authority under which it is signed or a notarially certified or office copy thereof, to **Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA**, so as to arrive no later than 11.00 a.m. (UK time) on 7 March 2025; or
2. you can register your proxy appointment and voting instructions by going to Equiniti's Shareview website, www.shareview.co.uk, and logging in to your Shareview Portfolio. To register for a Shareview Portfolio, go to www.shareview.co.uk and enter the requested information. Your electronic proxy appointment must be lodged by no later than 11.00 a.m. (UK time) on 7 March 2025. Please note that any electronic communication sent to the Company's registrar in respect of the appointment of a proxy that is found to contain a computer virus will not be accepted; or
3. if you hold your shares in uncertificated form, use the CREST electronic proxy appointment service as described below; or
4. if you are an institutional investor, use the Proxymity platform as described below.

Completion of the Form of Proxy or appointment of a proxy electronically or through CREST will not prevent a member from attending the Annual General Meeting in person.

Shares held in uncertificated form — electronic proxy appointment through CREST

CREST members who wish to appoint a proxy or proxies by utilising the CREST electronic proxy appointment service may do so for the Annual General Meeting and any adjournment(s) thereof by utilising the procedures described in the CREST Manual which can be found at www.euroclear.com. CREST personal members or other CREST sponsored members, and those CREST members who have appointed (a) voting service provider(s), should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf.

In order for a proxy appointment made by means of CREST to be valid, the appropriate CREST message (a "**CREST Proxy Instruction**") must be properly authenticated in accordance with Euroclear UK & International's specifications and must contain the information required for such instructions, as described in the CREST Manual. The message must be transmitted so as to be received by the issuer's agent, ID RA19, by 11.00 a.m. (UK time) on 7 March 2025. For this purpose, the time of receipt will be taken to be the time (as determined by the timestamp applied to the message by the CREST Applications Host) from which the issuer's agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST.

CREST members and, where applicable, their CREST sponsors or voting service providers should note that Euroclear UK & International does not make available special procedures in CREST for any particular messages. Normal system timings and limitations will therefore apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member or sponsored member or has appointed (a) voting service provider(s), to procure that their CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST sponsors or voting service providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings.

The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001 (as amended).

If you are an institutional investor you may be able to appoint a proxy electronically via the Proxymity platform, a process which has been agreed by the Company and approved by the Registrar. For further information regarding Proxymity, please go to www.proxymity.io. Your proxy must be lodged by 11.00 a.m. (UK time) on 7 March 2025 in order to be considered valid. Before you can appoint a proxy via this process you will need to have agreed to Proxymity's associated terms and conditions. It is important that you read these carefully as you will be bound by them and they will govern the electronic appointment of your proxy.

If you are a holder of the beneficial interest in ordinary shares registered in the name of Euroclear Nominees as custodian for DNB Bank ASA ("**DNB**") and held by DNB as nominee in The Norwegian Central Securities Depository (Euronext Securities Oslo), a DNB Proxy Form is enclosed which allows you to instruct DNB to instruct Euroclear Nominees either to appoint the Chairman of the AGM as its proxy to vote your ordinary shares at the AGM or alternatively to appoint you (or a third party nominated by you) to attend, speak and vote at the AGM. To be valid, a DNB Proxy Form must be received by DNB via e-mail in PDF format to vote@dnb.no (noting "Benchmark AGM" in the subject) or post to DNB Bank ASA, Registrars Department, P.O. Box 1600 Sentrum, 0021 Oslo as soon as possible and, in any event, by no later than 11.00 a.m. (UK time) (12.00 midday Central European time) on 28 February 2025.

Location of meeting

The Annual General Meeting will be held at the offices of DLA Piper UK LLP, 160 Aldersgate Street, London EC1A 4HT.

Questions

The Board is conscious that some shareholders may not be able to attend the Annual General Meeting. In order to facilitate shareholder engagement, if you are unable to attend but would like to ask the Board a question on the business of the Annual General Meeting, please submit your questions by email to AGM@bmkholdings.com, so as to arrive by 11.00 a.m. (UK time) on 7 March 2025. The Board will attempt to reply to any emails as soon as reasonably practicable. Responses will be made via return email or published on our investors' website at www.benchmarkplc.com/investors/, as deemed appropriate by the Board of Directors.

Electronic Communications

The Company actively encourages all shareholders to register for electronic communications to enable it to reduce the paper used when communicating with shareholders.

Recommendation

The Board believes that the resolutions to be put to the Annual General Meeting are in the best interests of the Company and its shareholders as a whole and, accordingly, recommends that the shareholders vote in favour of the resolutions, as the Directors intend to do in respect of their beneficial shareholdings in the Company.

Yours sincerely

Tripp Lane

Chairman

BENCHMARK HOLDINGS PLC

(Registered in England and Wales with no. 04115910)

Notice of Annual General Meeting

NOTICE is hereby given that the Annual General Meeting of Benchmark Holdings plc (the “**Company**”) will be held at the offices of DLA Piper UK LLP, 160 Aldersgate Street, London, EC1A 4HT at 11.00 a.m. on 11 March 2025 for the transaction of the following business:

To consider and, if thought fit, to pass the following resolutions, numbers 1 to 13 (inclusive) of which will be proposed as ordinary resolutions and numbers 14 to 16 (inclusive) of which will be proposed as special resolutions:

1. **THAT** the Company’s annual accounts for the financial year ended 30 September 2024, together with the Directors’ report and the auditors’ report on those accounts, be received.
2. **THAT** the Directors’ Remuneration Report for the year ended 30 September 2024 be received.
3. **THAT** KPMG LLP be reappointed as auditors of the Company to hold office from the conclusion of this Meeting until the conclusion of the next Annual General Meeting of the Company at which the accounts are laid.
4. **THAT** the Directors be authorised to determine the auditors’ remuneration.
5. **THAT** Mr Trond Williksen be re-elected as a Director.
6. **THAT** Ms Septima Maguire be re-elected as a Director.
7. **THAT** Mr Yngve Myhre be re-elected as a Director.
8. **THAT** Mr Kristian Eikre be re-elected as a Director.
9. **THAT** Mr Jonathan Esfandi be re-elected as a Director.
10. **THAT** Mr Torgeir Svae be re-elected as a Director.
11. **THAT** Ms Marie Danielsson be re-elected as a Director.
12. **THAT** Mr Nathan “Tripp” Lane be elected as a Director.
13. **THAT** for the purposes of section 551 of the Companies Act 2006 (the “**Act**”) (and so that expressions used in this resolution shall have the same meanings as in that section 551):
 - 13.1. the Directors be and are generally and unconditionally authorised to exercise all powers of the Company to allot shares and to grant such subscription and conversion rights as are contemplated by sections 551(1)(a) and (b) of the Act respectively up to a maximum nominal amount of £247,136 to such persons and at such times and on such terms as they think proper during the period expiring at the end of the next Annual General Meeting of the Company, or if earlier, the date falling 15 months after the passing of the resolution (unless previously revoked or varied by the Company in general meeting); and further
 - 13.2. the Directors be and are generally and unconditionally authorised to exercise all powers of the Company to allot equity securities (as defined in section 560 of the Act) in connection with a fully pre-emptive offer in favour of the holders of equity securities and any other persons entitled to participate in such issue where the equity securities respectively attributable to the interests of such holders and persons are proportionate (as nearly as maybe) to the respective number of equity securities held by them up to an aggregate nominal amount of £247,136 during the period expiring at the end of the next Annual General Meeting of the Company, or if earlier, the date falling 15 months after the passing of the resolution, subject only to such exclusions or other arrangements as the Directors may consider necessary or expedient to deal with fractional entitlements or legal or practical problems under the laws or requirements of any recognised regulatory body or stock exchange in any territory; and
 - 13.3. the Company be and is hereby authorised to make prior to the expiry of such period any offer or agreement which would or might require such shares or rights to be allotted or granted after the expiry of the said period and the Directors may allot such shares or grant such rights in pursuance of any such offer or agreement notwithstanding the expiry of the authority given by this resolution, so that all previous authorities of the Directors pursuant to the said section 551 be and are hereby revoked.
14. **THAT**, subject to the passing of resolution 13 set out in the Notice convening this Meeting, the Directors be and are empowered in accordance with section 570 of the Act to allot equity securities (as defined in section 560 of the Act) for cash, pursuant to the authority conferred on them to allot such shares or grant such rights by that resolution and/or where the allotment constitutes an allotment of equity securities by virtue of section 560(3) of the Act, as if section 561(1) and sub-sections (1) – (6) of section 562 of the Act did not apply to any such allotment, provided that the power conferred by this resolution shall be limited to:
 - 14.1. the allotment of equity securities in connection with an issue or offering in favour of holders of equity securities (but in the case of the authority granted under paragraph 13.2 by way of a fully pre-emptive offer only) and any other persons entitled to participate in such issue or offering where the equity securities respectively attributable to the interests of such holders and persons are proportionate (as nearly as may be) to the respective number of equity securities held by or deemed to be held by them on the record date of such allotment, subject only to such exclusions or other arrangements as the Directors may consider necessary or expedient to deal with fractional entitlements or legal or practical problems under the laws or requirements of any recognised regulatory body or stock exchange in any territory; and
 - 14.2. the allotment (otherwise than pursuant to paragraph 14.1 above) of equity securities up to an aggregate nominal value not exceeding £37,070,
and this power, unless renewed, shall expire at the end of the next Annual General Meeting of the Company, or if earlier, the date falling 15 months after passing of this resolution, but shall extend to the making, before such expiry, of an offer or agreement which would or might require equity securities to be allotted after such expiry and the Directors may allot equity securities in pursuance of such offer or agreement as if the authority conferred hereby had not expired.

15. **THAT**, subject to the passing of resolution 13 set out in the Notice convening this Meeting, the Directors be and are empowered in accordance with section 570 of the Act and in addition to any authority granted under resolution 14, to allot equity securities (as defined in section 560 of the Act) for cash, pursuant to the authority conferred on them to allot such shares or grant such rights by resolution 13 and/or where the allotment constitutes an allotment of equity securities by virtue of section 560(3) of the Act, as if section 561(1) and sub-sections (1) – (6) of section 562 of the Act did not apply to any such allotment, provided that the power conferred by this resolution shall be:
- 15.1. limited to the allotment of equity securities up to an aggregate nominal value not exceeding £37,070; and
 - 15.2. used only for the purposes of financing (or refinancing if the authority is to be used within 12 months after the original transaction) a transaction which the Board of Directors of the Company determines to be an acquisition or other capital investment of a kind contemplated by the Statement of Principles on Disapplying Pre-Emption Rights most recently published by the Pre-Emption Group prior to the date of this notice,
- and this power, unless renewed, shall expire at the end of the next Annual General Meeting of the Company, or if earlier, the date falling 15 months after passing of this resolution, but shall extend to the making, before such expiry, of an offer or agreement which would or might require equity securities to be allotted after such expiry and the Directors may allot equity securities in pursuance of such offer or agreement as if the authority conferred hereby had not expired.
16. **THAT** the Company be and is hereby generally and unconditionally authorised for the purpose of section 701 of the Act to make market purchases (as defined in section 693 of the Act) of ordinary shares of £0.001 each in the capital of the Company ("**ordinary shares**") provided that:
- 16.1. the maximum number of ordinary shares hereby authorised to be purchased is 74,141,019;
 - 16.2. the minimum price (exclusive of expenses) which may be paid for such ordinary shares is £0.001 per share, being the nominal amount thereof;
 - 16.3. the maximum price (exclusive of expenses) which may be paid for such ordinary shares shall be an amount equal to the higher of (i) 5 per cent. above the average of the middle market quotations for such shares taken from the AIM Appendix to The London Stock Exchange Daily Official List for the five business days immediately preceding the day on which the purchase is made and (ii) the higher of the price of the last independent trade of an ordinary share and the highest current independent bid for an ordinary share as derived from the trading venue where the purchase is carried out;
 - 16.4. the authority hereby conferred shall (unless previously renewed or revoked) expire on the earlier of the end of the next Annual General Meeting of the Company and the date which is 15 months after the date on which this resolution is passed; and
 - 16.5. the Company may make a contract to purchase its own ordinary shares under the authority conferred by this resolution prior to the expiry of such authority, and such contract will or may be executed wholly or partly after the expiry of such authority, and the Company may make a purchase of its own ordinary shares in pursuance of any such contract.

BY ORDER OF THE BOARD

Ivonne Cantu

Company Secretary

Date: 11 February 2025

Registered Office: Highdown House, Yeoman Way, Worthing, West Sussex BN99 3HH

Notes:

- (i) A member entitled to attend and vote at the Meeting convened by the above Notice is entitled to appoint a proxy to exercise all or any of the rights of the member to attend and speak and vote on their behalf. A proxy need not be a member of the Company. A member may appoint more than one proxy in relation to the Meeting, provided that each proxy is appointed to exercise the rights attached to a different share or shares held by that member.
 - (ii) To appoint a proxy you may:
 - (a) use the Form of Proxy enclosed with this Notice of Annual General Meeting. To be valid, the Form of Proxy, together with any power of attorney or other authority (if any) under which it is signed or a notarially certified or office copy of the same, must be received by post or (during normal business hours only) by hand at Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA, so as to arrive no later than 11.00 a.m. (UK time) on 7 March 2025 (excluding non-working days);
 - (b) It is possible for you to submit your proxy votes online by going to Equiniti's Shareview website, www.shareview.co.uk, and logging in to your Shareview Portfolio. Once you have logged in, simply click 'View' on the 'My Investments' page and then click on the link to vote and follow the on-screen instructions. If you have not yet registered for a Shareview Portfolio, go to www.shareview.co.uk and enter the requested information. It is important that you register for a Shareview Portfolio with enough time to complete the registration and authentication processes. Please note that any electronic communication sent to the Company's registrar in respect of the appointment of a proxy that is found to contain a computer virus will not be accepted;
 - (c) if you hold your shares in uncertificated form, use the CREST electronic proxy appointment service as described on page 4 of the circular of which this Notice of Annual General Meeting forms part; or
 - (d) if you are an institutional investor you may be able to appoint a proxy electronically via the Proxymity platform, a process which has been agreed by the Company and approved by the Registrar. For further information regarding Proxymity, please go to www.proxymity.io. Your proxy must be lodged by 11.00 a.m. (UK time) on 7 March 2025 in order to be considered valid. Before you can appoint a proxy via this process you will need to have agreed to Proxymity's associated terms and conditions. It is important that you read these carefully as you will be bound by them and they will govern the electronic appointment of your proxy.
- Completion of the Form of Proxy or the appointment of a proxy electronically or through CREST will not prevent a member from attending and voting in person.
- (iii) If you are a holder of the beneficial interest in ordinary shares registered in the name of Euroclear Nominees as custodian for DNB and held by DNB as nominee in The Norwegian Central Securities Depository (Euronext Securities Oslo), a DNB Proxy Form is enclosed. To be valid, a DNB Proxy Form must be received by DNB via e-mail in PDF format to vote@dnb.no (noting "Benchmark AGM" in the subject) or post to DNB Bank ASA, Registrars Department, P.O. Box 1600 Sentrum, 0021 Oslo as soon as possible and, in any event, by no later than 11.00 a.m. (UK time) (12.00 midday Central European time) on 28 February 2025.
 - (iv) Pursuant to Regulation 41 of the Uncertificated Securities Regulations 2001 (as amended), only shareholders registered in the register of members of the Company as at 6.30 p.m. on 7 March 2025 shall be entitled to attend and vote at the Annual General Meeting in respect of the number of shares registered in their name at such time. If the Meeting is adjourned, the time by which a person must be entered on the register of members of the Company in order to have the right to attend and vote at the adjourned Meeting is 6.30 p.m. on the day prior to the day immediately before the date fixed for the adjourned meeting. Changes to the register of members after the relevant times shall be disregarded in determining the rights of any person to attend and vote at the Meeting.
 - (v) If you are a holder of the beneficial interest in ordinary shares registered in the name of Euroclear Nominees as custodian for DNB and held by DNB as nominee in The Norwegian Central Securities Depository (Euronext Securities Oslo), to be entitled to vote at the meeting (and for the purpose of determining the number of votes you may cast), you must be entered on the Company's register of shareholders holding through The Norwegian Central Securities Depository (Euronext Securities Oslo) as at end of day on 27 February 2025. Changes to entries on the register after 6.30 p.m. (UK time) (7.30 p.m. Central European Time) on 27 February 2025 shall be disregarded in determining the right of any person to attend or vote at the AGM.
 - (vi) In the case of joint holders, the vote of the senior holder who tenders a vote whether in person or by proxy shall be accepted to the exclusion of the votes of the other joint holders and, for this purpose, seniority shall be determined by the order in which the names stand in the register of members of the Company in respect of the relevant joint holding.
 - (vii) You may not use any electronic address provided either in the above Notice or any related documents (including the Form of Proxy) to communicate with the Company for any purposes other than those expressly stated.
 - (viii) Copies of the terms and conditions of appointment of the Directors are available for inspection at the registered office of the Company, Highdown House, Yeoman Way, Worthing, West Sussex, BN99 3HH during usual business hours on any weekday (Saturdays, Sundays and public holidays excluded) until the conclusion of the Annual General Meeting and will be available for inspection at the place of the Annual General Meeting for at least 15 minutes prior to and during the Annual General Meeting.
 - (ix) Unacceptable behaviour will not be tolerated at the Annual General Meeting and it will be dealt with appropriately by the Chairman.
 - (x) As at 7 February 2025 (being the last practicable day prior to the publication of this Notice) the Company's issued share capital consists of 741,410,190 ordinary shares, carrying one vote each. Therefore, the total voting rights in the Company as at 7 February 2025 are 741,410,190.